JEANTET ADVISES THE CHINA MEDICAL SYSTEM GROUP ON ITS ACQUISITION OF A STAKE IN THE COMPANY EYE TECH CARE
Paris, September 15, 2022 – Jeantet has advised the Chinese group China Medical System in the context of (i) a stake and acquisition of a stake, through certain group subsidiaries, of approximately 33.4% of the share capital of the French company Eye Tech Care and (ii) the signing of a licensing, collaboration and distribution agreement for the EyeOP1® ultrasound glaucoma treatment device.
Based in Shenzhen, the China Medical System group is a leader in the development and distribution of new medical treatments, particularly in the areas of dermatology and ophthalmology. The operation aims to provide a new, high-quality treatment option for glaucoma patients in China and Southeast Asian countries.
Founded in 2008 in Lyon by experts in the field of therapeutic ultrasound and in partnership with INSERM, Eye Tech Care is dedicated to the application of therapeutic ultrasound technology in the fight against glaucoma, developing and promoting the EyeOP1® glaucoma treatment device for the non-invasive treatment by UCP® of this ophthalmological disease.
The Jeantet team was composed of Thierry Brun, (Partner), Maxime Brotz (Counsel), Pak-Hang Li , You Shang and Maria Plakci (Associates), for the Corporate/Mergers & Acquisitions aspects.
Eye Tech Care was advised by CMS Francis Lefebvre Avocats with Xinyu Hu and David Mantienne (Counsels), Yanchao Wu (Associate), for the Corporate/Mergers & Acquisitions aspects, Johann Roc'h and Henri Bitar (Partners) for the tax aspect, Nicolas Zhu (Partner – CMS Shanghai), and Laila Lu (Associate – CMS Shanghai), for the contract law aspects.